Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaConstantine S. Tam, Andrew W. Roberts, Mary Ann Anderson et al.|New England Journal of Medicine|2018Cited by 429
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paperMassimo Cristofanilli, Klaus Pantel, Jean‐Yves Pierga et al.|Critical Reviews in Oncology/Hematology|2018Cited by 268
Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphomaRishu Agarwal, Sarah‐Jane Dawson, Yih-Chih Chan et al.|Nature Medicine|2018Cited by 204
Non-genetic determinants of malignant clonal fitness at single-cell resolutionKatie Fennell, Mark A. Dawson, Dane Vassiliadis et al.|Nature|2021Cited by 160
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell DeathSylvain Garciaz, Mark A. Dawson, Andrew A. Guirguis et al.|HAL (Le Centre pour la Communication Scientifique Directe)|2023Cited by 34